Venture capital fund · 2 deals
Every published round Novo Ventures took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
| Company | Stage | Announced | Amount | Role | Alongside | Sources |
|---|---|---|---|---|---|---|
| Loose Cannon | Series A | 11 Jan 2023 | $12m | Lead | SmartCompany, Startup Daily | |
| Spinifex Pharmaceuticals | Series C | 13 May 2014 | US$45m (A$48.3m) | Participant | bionity.com, GBS Ventures (30 Jun 2015), clinicalleader.com, GBS Ventures (13 May 2014) |
Companies Novo Ventures has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| Spinifex Pharmaceuticals | UQ spin-out sold to Novartis in 2015 | 13 May 2014, Series C | 1 | 0 |
| Loose Cannon | 11 Jan 2023, Series A | 1 | 1 |
Fund closes reported for Novo Ventures, as distinct from the investments it has made.
Companies Novo Ventures has backed that another company then bought. An exit for the holding, not a deal Novo Ventures did.
| Company | Bought by | Kind | Announced | Price |
|---|---|---|---|---|
| Spinifex Pharmaceuticals | Novartis International | Acquisition | 29 Jun 2015 | US$200m+ (A$260m+) |
| Spinifex Pharmaceuticals | Novartis | Acquisition | 29 Jun 2015 | US$700m (A$911m) |
Stories naming Novo Ventures. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Early-2023 roundup of startup raises: a solar software company closed a Series B, an adventure-tech firm landed Series A money, and an angel investing platform raised seed capital.
Milo radio maker Loose Cannon Systems has raised a A$12 million Series A led by De Novo Ventures with XT Ventures. Founder Peter Celinski previously sold Avega Systems to Altec Lansing and earlier crowdfunded US$2.5 million.
Also SmartCompany
GBS Ventures reports Novartis has agreed to acquire chronic-pain drug developer Spinifex Pharmaceuticals for US$200 million upfront plus milestones, recalling the company's 2005, 2008 and 2014 venture rounds and its Australian investors.
Also GBS Ventures·novartis.com·clinicalleader.com·Startup Daily·Startup Daily·anthillonline.com·@AuManufacturing·materresearch.org.au·Business News Australia